![](/images/graphics-bg.png)
Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population
المؤلفون المشاركون
Nashwan, Abd al-Qadir J.
Yusuf, Zuhayb
Ata, Fatin
Zahir, Fatimah Z.
Babakr, Anas Muhammad
Faruqi, Amir Ali
al-Hayyari, Musa Ahmad
al-Buzum, Adil Isam
Muhammad, Ahmad Hatim
Yasin, Muhammad A.
المصدر
العدد
المجلد 2022، العدد 3 (31 ديسمبر/كانون الأول 2022)، ص ص. 1-9، 9ص.
الناشر
تاريخ النشر
2022-12-31
دولة النشر
قطر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management.
The response rate for Rituximab is variable in different populations ranging from 30% to 90%.
The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation.
Methods: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care & Research.
The study included patients with chronic refractory ITP who received rituximab as second-line therapy.
Descriptive and summary statistics were used to describe the sociodemographic parameters of the study cohort.
Results: Of the 41 patients with chronic ITP, 26 were Arabs, 12 were Asians, and 3 were of other ethnicities.
Rituximab was associated with an overall response rate of 80.4%.
Arabic patients had the highest clinical response (84.6%) among the ethnicities with the lowest adverse effects (11.5%).
Asians had a response rate of 66.6%, and adverse effects were seen in 16.7% of the patients.
Conclusions: In chronic refractory ITP, rituximab appears to have a better clinical response in the Arabic population with minimal toxicity than in other ethnicities.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ata, Fatin& Yusuf, Zuhayb& Zahir, Fatimah Z.& Babakr, Anas Muhammad& Faruqi, Amir Ali& al-Hayyari, Musa Ahmad…[et al.]. 2022. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population. Qatar Medical Journal،Vol. 2022, no. 3, pp.1-9.
https://search.emarefa.net/detail/BIM-1437634
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ata, Fatin…[et al.]. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population. Qatar Medical Journal No. 3 (2022), pp.1-9.
https://search.emarefa.net/detail/BIM-1437634
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ata, Fatin& Yusuf, Zuhayb& Zahir, Fatimah Z.& Babakr, Anas Muhammad& Faruqi, Amir Ali& al-Hayyari, Musa Ahmad…[et al.]. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity : a descriptive study among the Arabic population. Qatar Medical Journal. 2022. Vol. 2022, no. 3, pp.1-9.
https://search.emarefa.net/detail/BIM-1437634
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 8-9
رقم السجل
BIM-1437634
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)